This article is more than 5 years old. Information may no longer be current.
Study: Myocardial viability imaging, CABG effectiveness not linked
Click Here to Manage Email Alerts
American College of Cardiology 60th Annual Scientific Sessions
NEW ORLEANS – Myocardial viability imaging was not associated with the effectiveness of CABG, results from a viability substudy of the STICH trial indicated.
Researchers for the substudy recruited 601 patients from the STICH study and assigned them to undergo either nuclear perfusion scanning or dobutamine echocardiography. Of those, 487 were determined to have myocardial viability (243 assigned to medical therapy and 244 to CABG) and 144 patients did not have myocardial viability (60 assigned to medical therapy and 54 to CABG).
Although the death rate was 37% among patients with myocardial viability (P=0.003) and 51% among patients without myocardial viability, the association became statistically insignificant when baseline characteristics were adjusted for (P for interaction=0.528).
“Imaging may be important in individual patients, but there are many other factors that contribute to outcomes in patients with CAD and HF with or without surgery,” Robert O. Bonow, MD, professor of medicine and director of the Center for Cardiovascular Innovation at Northwestern University in Chicago, told Cardiology Today. “These include comorbidities like kidney failure, diabetes and overall left ventricular function that are more important factors in a multivariable analysis than just the myocardial viability data alone.” – by Eric Raible
For more information:
- Bonow R. LBCT II, Session 3013. Presented at: ACC 60th Annual Scientific Sessions; April 2-5, 2011; New Orleans.
Disclosure: Dr. Bonow reports no relevant financial disclosures.
 |
Follow CardiologyToday.com on Twitter. |